Scarica l'app Stockscreener
64.29
0.16%
-0.10
Pre-mercato:
64.00
-0.29
-0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$64.39
Aprire:
$65.1
Volume 24 ore:
1.25M
Relative Volume:
0.84
Capitalizzazione di mercato:
$5.32B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-10.82
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-5.12%
1M Prestazione:
-13.02%
6M Prestazione:
+10.83%
1 anno Prestazione:
+24.11%
Intervallo 1D:
$63.50
$65.62
Intervallo di 1 settimana:
$63.49
$69.43
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
64.29 | 5.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics, Inc. (PTCT) - DirectorsTalk Interviews
Oversold Conditions For PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Gains Edge as Competitor Faces Setback - GuruFocus
PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Should I Buy - Intellectia AI
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat
PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc. - MarketBeat
PTC Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 earnings call transcript - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally - MSN
How Translarna NDA Withdrawal and Mixed Results Will Impact PTC Therapeutics (PTCT) Investors - Sahm
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 24.21% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CLO Boulding sells 3,019 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
Morgan Stanley raises PTC Therapeutics stock price target on OpEx cuts - Investing.com Australia
PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations - Yahoo Finance
PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc. - MarketBeat
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB - MarketBeat
PTC Therapeutics (PTCT) Q4 earnings: Taking a look at key metrics versus estimates - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
PTC Therapeutics (NASDAQ:PTCT) Cut to "Hold" at Wall Street Zen - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock - MarketBeat
Lee Scott Golden Sells 2,484 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 3,056 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,992 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 7,371 Shares of Stock - MarketBeat
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Trading Down 6.5% on Disappointing Earnings - MarketBeat
PTC Therapeutics (PTCT): RBC Capital Lowers Price Target to $82 - GuruFocus
Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $93.00 - MarketBeat
B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus
PTC Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PTC Therapeutics Inc (PTCT) Q4 2025 Earnings Call Highlights: Su - GuruFocus
PTC Therapeutics exec. VP Boulding sells $408,612 in stock By Investing.com - Investing.com Canada
PTC Therapeutics exec. VP Boulding sells $408,612 in stock - Investing.com Australia
Decoding PTC Therapeutics Inc (PTCT): A Strategic SWOT Insight - GuruFocus
PTC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Q4 Earnings Call Highlights - MarketBeat
PTC Therapeutics earnings missed by $1.41, revenue fell short of estimates - Investing.com Canada
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):